I respectfully disagree. You’ve complained ad nauseam (on iHub and SI) about the 10b5-1 sales during the past few years, which I would characterize as over-focusing on a small matter.
I don’t think the existence of the 10b5-1 plans has anything to do with insiders’ expectations about Lovenox competition.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”